Paul Korner, MD, MBA

Paul Korner is physician executive with over 21 years of pharmaceutical/biotech industry experience, serving in senior R & D leadership position for Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics and Axovant Gene Therapies. He is currently the Chief Medical Officer of Agile Therapeutics, Inc. He has been responsible for multiple INDs/CTAs and more than 50 clinical trials (phase 1-4), leading to marketing authorization/approvals of 10 products including VYONDYS 53® (golodirsen) and several others. While serving as SVP Clinical & Medical Affairs at Axovant Gene Therapies, he advanced two gene therapy programs into IND and BLA enabling clinical trials for GM1 and GM2 gangliosidosis. He has been part of the LVP team for more than 3 years, providing strategic and operational scientific/clinical guidance to portfolio companies.

Dr. Korner has experience across novel pathways including gene therapy, vaccines, small molecules, peptides, and biologics across all development phases and multiple therapeutic areas including rare disease, CNS, women’s health, gastroenterology, nephrology, musculoskeletal/inflammation/orthopedics, and urology. Over the course of his career, he has authored fifty-one peer-reviewed publications across multiple disease states.

Dr. Korner is a board-certified obstetrician and gynecologist who was in private practice in Glencoe Illinois and Riverdale Georgia prior to joining industry in 1998. He received his B.S. in Biology from the University of Illinois (Champaign/Urbana), M.D. from Loyola University, Stritch School of Medicine in Maywood Illinois. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.